In his inaugural J.P. Morgan Healthcare Conference speech, newly minted Dexcom CEO Jake Leach looked to ease concerns over ...

In July, Leach was tapped to take the CEO role permanently at the start of 2026 as part of Dexcom’s planned succession ...

Investing.com - 摩根士丹利在 DexCom (NASDAQ:DXCM) 发布2025年第四季度初步业绩后，重申了对该公司的"增持"评级和75.00美元的目标价。

DexCom, Inc. DXCM is scheduled to report third-quarter 2025 resultson Oct. 30, after the closing bell. In the last reported quarter, the company’s adjusted earnings per share (EPS) of 48 ...

New Ontario Drug Benefit (ODB) coverage means eligible Ontarians who take insulin can now benefit from using Dexcom G7 to simplify management of their diabetes. Dexcom, Inc. (NASDAQ: DXCM), a global ...

"JPM26: Dexcom’s new CEO eyes international CGM markets for 2026 growth" was originally created and published by Medical ...

DexCom, Inc. DXCM reported strong preliminary results for the fourth quarter and full-year 2025. Despite the robust ...

2025财年全年，DexCom初步未经审计的收入总额约为46.6亿美元，较2024年增长16%。公司重申了2025年非通用会计准则毛利率约为61%的指引，以及非通用会计准则营业利润率为20-21%的指引。

Dexcom Reports Preliminary, Unaudited Results for the Fourth Quarter and Fiscal Year 2025 and Initial 2026 Outlook ...

DexCom, Inc. (NASDAQ:DXCM) is one of the Best Fundamental Stocks to Buy According to Analysts. On January 12, the company ...